In our latest update of the evidence on smoking bans and heart disease we summarize 59 studies. We take account of the underlying trends in incidence rates as far as possible by using control data in eight studies, and by adjustment based on observed trends in cases pre-and post-ban in 40 studies, being unable to make an adjustment in the remaining 11 studies. Overall, based on 62 independent estimates from the 59 studies, we estimate that bans reduce incidence by 5.0% (95% CI 3.2-6.8%), though this estimate reduces to 2.9% (0.01-5.6%) when we exclude regional estimates where national estimates are available, and studies where trend adjustment is not possible. For 25 of the studies, quadratic rather than linear adjustment is possible, but this hardly affects the overall estimates. Ban effects are somewhat greater when the pre-ban period studied is relatively short, and in smaller studies. We compare our findings with those in other recent reviews, one of which totally ignored underlying trends and results from control populations. We discuss reasons why we believe there is likely to be a true small effect of smoking bans, and weaknesses in the data which preclude reaching any very confident conclusion.
Introduction
Smoking bans are public policies that prohibit smoking in workplaces and other public places. Although there have been attempts to forbid smoking in various situations going back to the 16th century, we limit attention here to the effects of bans brought in after the adverse health effects of smoking began to become clear, and concern arose about possible effects of passive smoking on the nonsmoker. The first such ban, the Minnesota Clean Indoor Air Act, was introduced in 1975 and bans have, by now, been introduced in many countries of the world.
Given the high incidence of heart disease, the evidence that its risk is increased in smokers (US Surgeon General, 2004) and to some extent in passive smokers (Lee et al., 2017) , and the evidence that the risk increase in smokers declines quite rapidly on quitting (Lee et al., 2012; US Surgeon General, 1990) , studies of the possible effects of smoking bans on heart disease have proliferated. These are underpinned by studies that have demonstrated that smoking bans lead to a reduction in the prevalence of smoking and consumption per smoker (Callinan et al., 2010) and to reduced levels of cotinine, the major metabolite of nicotine, in nonsmokers (Haw and Gruer, 2007; Pechacek et al., 2007) .
Since the first study of the effect of smoking bans on heart disease risk (Sargent et al., 2004) , we have published two previous reviews of the rapidly proliferating evidence. Our first review (Lee and Fry, 2011) used a consistent approach to derive estimates of the ban effect, using evidence from twenty-four studies, and taking into account time trends and data from control areas. Preferring national estimates to regional estimates where available, we estimated a 5% reduction in risk (95% confidence interval [CI] 3%-8%) associated with the introduction of a ban, which reduced to 2.7% (2.1%-3.4%) when we omitted estimates where trend adjustment was not possible. In 2014, now including evidence from forty-five studies , we incorporated some new features in our analyses. These included consideration of underlying non-linear trends, a modified trend adjustment method where there were multiple time periods post-ban, comparison of estimates based both on changes in rates and in numbers of cases, and comparison of estimates according to the degree of smoking restrictiveness. Here the reduction was estimated as 4.2% (1.8%-6.5%) using a consistent approach, an estimate which reduced to 2.6% (1.1%-4.0%) excluding regional estimates if national estimates were available, and studies where trend adjustment was not possible.
In this, our third review, we use techniques similar to those used in our second review to extend the analyses to include more recent evidence. We also update our discussion of the various uncertainties and possibilities of bias in the evidence. Discussion of reviews by other authors (e.g. Glantz, 2008 Lightwood and Glantz, 2009; Lin et al., 2013; Mackay et al., 2010; Meyers et al., 2009; Tan and Glantz, 2012) are included in our two previous publications. Here we also consider the latest reviews (Frazer et al., 2016; Jones et al., 2014) .
Methods
All methods used are consistent with our previous review , except where defined below.
Literature searches
Published studies and reviews relating smoking bans to risk of AMI (or heart disease) additional to those considered earlier (Lee and Fry, 2011; Lee et al., 2014) were sought from PubMed searches (January 1st, 2012 to November 24th, 2017) using the terms described by Mackay et al. (2010) , and also from papers cited in relevant publications.
Quantifying levels of restrictiveness
Except for local US studies and for studies presenting overall results based on multiple bans in different locations), we sought published scores for restrictiveness before and after the ban. We used the method of Chriqui et al. (2002) without pre-emption, or a modification of it (ANSR (American Nonsmokers' Rights Foundation), 2009) for US studies, and the method of Joossens and Raw (2006) for European studies, re-expressing each score as a percentage. Where published scores were unavailable, we conducted internet searches to supplement the descriptions of the ban given in the study publication(s), and estimated the scores using the Chriqui system.
General approach
The approach used can be summarized as follows:
• We do not consider mortality, restricting attention to AMI admission rates or near equivalents (as described in Lee et al. (2014) ).
• We compare observed numbers of AMI cases post-ban with numbers expected without a ban, referring to the ratio as the "ban effect" or the ban relative risk (RR).
• We allow for the risk of AMI to vary seasonally by comparing numbers of pre-and post-ban for whole years or the same periods in a year or using results adjusted for season or factors linked to it.
• We reject studies not accounting for seasonal variation. In view of the strong relationship of season to AMI admission rates, studies which compared pre-and post-ban periods of only a few months covering the difference seasons of the year, with no seasonal adjustment possible, provided no useful information.
• We adjust for any underlying time trend in AMI rates, preferring data for a control population where trends are likely to be similar to carrying out adjustment for trend.
• We test the effect of adjusting for non-linear as well as linear trend, where the data are adequate to do this.
• We consider factors such as changes in diagnostic criteria, which might affect the time trend.
• We generally consider the post-ban period as starting immediately or just after the ban.
• Where multiple publications present results relating to the same ban in the same area, but for differing follow-up periods, those from the publication describing results for the longer follow-up periods were used.
• Where data for multiple control populations are available, we generally estimate the ban effect from the combined control data, though in some cases control populations with obvious weaknesses may be excluded. An example of this might be where a control population had a different smoking restriction, rather than being a no-ban area.
• Our meta-analyses are always based on results for the whole study population, not on results for subsets by e.g. sex, age or smoking habit.
• Results for a study relating to different ban times in different areas are reported separately.
• The methodology used assumes the effect of a ban is to multiply the risk of AMI by a factor which is invariant of the length of time postban, though this assumption is investigated by comparing ban effects in studies with shorter and longer post-ban periods.
Estimating the ban effect
To assist the understanding of the reader we reproduce below the relevant section in our earlier paper 
No control data and no trend information present
The RR associated with a ban, and the variance of its logarithm, are estimated by:
and
where M refers to the mean number of cases per year (or period of interest), N refers to the total number of cases, the subscripts A and B refer to the period after and before the ban, and the subscript T refers to the test (ban) area. The 95% CIs are estimated by
where Z is the standard normal deviate corresponding to 0.025. Though seasonal effects are taken into account, provided the periods considered cover the same months of the year, no account is taken of any underlying trend pre-ban, so estimates using formula 1 are considered less reliable than those taking trend into account.
Control data present
The RR and the variance of its logarithm are estimated by
where the subscript C refers to the control (no ban) area, and
with the lower and upper 95% CI of RR 1 estimated by
These formulae assume that the lengths of the pre-and post-ban periods for the test area are the same as for the control area, so seasonal effects automatically cancel out. Any underlying trend is accounted for by assuming that the trend in the control area would also have been observed in the test area in the absence of a ban.
No control data, and adjustment for linear trend possible
Where data are available on the number of cases occurring in successive periods pre-ban and in one or more periods post-ban, Poisson log-linear regression analysis (Draper and Smith, 1998) was performed using SAS Version 9.2 (SAS Institute Inc., 2009). The log of the number of deaths seen pre-and post-ban was modelled as a linear effect over year, with a dummy variable included, set to zero pre-ban and one post- Lee et al. Regulatory Toxicology and Pharmacology 101 (2019) 172-186 ban. With no effect of the ban, the estimate for this dummy variable should be zero. However if there was an offset to the linear trend caused by the ban, this estimate will give a value for the effect. As the Poisson model in SAS models the deaths in terms of log number of deaths, the ban effect, RR 3 , is given by the exponential of the estimate, with the 95% CI derived from its standard error (SE 3 ):
The methodology assumes that each period covers the same months of the year, so seasonal effects are not an issue.
Note that the methods described above (loosely referred to below as formula 3) can also be applied where control data are available, providing that pre-ban data are available for successive periods, simply by ignoring the control area data.
The methodology described above is based on the numbers of cases occurring in each period, ignoring changes in population size. Where population data are available for each period, the method is adapted by adding the log of the population as an offset to the model. The relative risk and CIs are estimated from the dummy variable as above.
No control data, and adjustment for non-linear trend possible
Where data are available on the number of cases for at least three periods pre-ban and in one or more periods post-ban, the same methods are used, except that the prediction equation includes years squared as a quadratic term.
Meta-analyses
Independent RR estimates from multiple studies are combined using random-effects meta-analysis (which allows for the true effect to vary from study to study), weighted on the inverse of the variances of the RRs. The meta-analyses are performed using the R package 'meta' version 4.9 rather than SAS as used in the previous paper. This resulted in minor differences in the estimates and confidence regions. Results of fixed-effect meta-analysis (which assumes that there is one true effect size shared by all the studies considered) are also shown. Meta-analyses are also conducted separately by type of estimate (with no control data or trend information present, with control data present, or with no control data but adjustment for linear trend possible). They also investigate variation by region, study weight, the lengths of the pre-ban and post-ban periods, change in restrictiveness following the ban, and the age range of the population studied. Meta-analyses are also conducted excluding regional estimates where national estimates are available and omitting estimates where trend adjustment was not possible. The meta-analyses carried out were defined in advance. Valentino et al. (2010 Valentino et al. ( , 2011a but based on fewer years postban and giving the ban date as 13th April 06.
P.N. Lee et al. Regulatory Toxicology and Pharmacology 101 (2019) 172-186 3. Results Table 1 gives, for each study identified as relevant, the location of the study area (and the control area if applicable), the timing of the ban, and the periods pre-and post-ban for which data are available. The studies are identified by codes S1 to S59. Studies S1 to S41 are 41 of the 45 studies identified in our previous review . Studies S49, S50 and S53 are also studies identified in our previous review, but where additional data had been presented in a more recent publication detected in our latest PubMed search. Study 51, which gives results for Madrid and Barcelona, supersedes an earlier paper (Villalbí et al., 2009) which gave results for Barcelona only. The 15 studies S42-S48, S52 and S54-S59 are new studies. A further 11 publications were also examined, following exclusion of irrelevant or previously considered studies based (continued on next page) P.N. Lee et al. Regulatory Toxicology and Pharmacology 101 (2019) 172-186 on abstracts, but were rejected: four as they considered mortality only (Cox et al., 2014; Ong et al., 2017; Stallings-Smith et al., 2014; Thach et al., 2016) ; four as being only comments and providing no new data (Arnett and Dunn, 2013; Geach, 2014; Huesch, 2013; Hurt et al., 2013) , one as giving no data on time trends (Shiue, 2014) , one for only giving data on ambulance calls (Glantz and Gibbs, 2013) and one for being very small, based only in one hospital (Morito et al., 2015) .
Literature searching

Study characteristics
National estimates are available for 17 countries, 11 in EuropeDenmark, England, Finland, France, Ireland, Italy, Malta, Portugal, Scotland, Spain and Switzerland -four in the Americas -Chile, Panama, Uruguay and USA, and also in New Zealand and Taiwan. Only regional estimates are available for Argentina, Canada, China, Germany, Netherlands and Turkey. Twenty three studies were conducted in the USA, five in Italy, four in Switzerland and three in Spain, with other countries having only one or two studies. The studies in the USA varied widely in their coverage, from nationally to a specific location in a state. Most of the bans occurred in 2002-2010, though some of the studies in the USA (S16, S27, S33) and the study in Taiwan (S59) considered earlier bans, and studies in Spain (S44) and Chile (S57) considered slightly later bans. Most studies considered only a single ban, but some studies considered bans at different times in multiple a Reference for main endpoint. b ACE = acute coronary events, AMI = ACS = acute coronary syndrome, AMI = acute myocardial infarction, CHD = coronary heart disease, IHD = ischaemic heart disease, SCA = sudden circulatory arrest. c C1 -rating system from Chriqui et al. (2002) locations, or successive bans in the same location. Table 2 gives further study details on the age of the populations studied, the endpoint used, and availability or estimates for study subsets, and the restrictiveness scores. Twenty-six studies considered the whole age range, 25 excluded children or younger adults where the risk of heart disease would be quite small, six concerned a defined age range, and two restricted attention to ages 65 + years.
Although only the combined results are used in our analyses, 26 studies presented results for study subsets, most commonly by age and/ or sex.
Of the 59 studies, 45 had AMI as the main endpoint, with 33 based on admissions, seven on discharges, three on incidence and three on other definitions. Of the remaining 14 studies, eight considered ACS admissions and six alternative endpoints.
It was possible to determine restrictiveness scores for 45 studies, using the Joossens and Raw system (Joossens and Raw, 2006) in 25 studies, the Chriqui system (Chriqui et al., 2002) in 19 studies and the modified Chriqui system (American Lung Association, 2009) in one study. Differences in restrictiveness scores pre-and post-ban varied from 17 to 95 (median 45%).
Further details of each study are given in Appendix A. Apart from giving details of the nature of the ban and the results reported by the authors, reference is made to weaknesses in the original estimates and to why (where relevant) some subsets of the study were rejected. Additionally, a clear description is given of how the main RR estimate we used was derived.
Studies where adjustment for trend was not possible
In 11 studies, conducted in 10 countries, adjustment for time trend was not possible, as there was no control area, or data for only one time period pre-ban. Table 3 gives, for each study, the mean number of cases per year pre-and post-ban, and the ban effect RR derived using formula 1 (as described in section 2.4), or based on estimates provided by the author. Of the 12 RR estimates (study S26 presenting results for two locations), 10 were below 1, seven significantly so (at p < 0.05), with the random-effects meta-analysis estimate 0.89 (95% CI 0.83-0.95). The estimate from study S42 clearly differs markedly from the others, and omitting it as an outlier increases the estimate to 0.92 (0.88-0.96).
Studies using control data
Our earlier review presented ban effect estimates from eight studies, all in the USA, derived using data for a control population where no ban was in force. Table 4 presents these results with the slightly changed random-effects estimate of 0.79 (95% CI 0.68-0.92).
Studies adjusting for linear trend
There were 40 studies without control data for which results adjusted for linear trend were available, being either provided by the authors themselves or derived by us. Fourteen studies were conducted in the USA, with five in Italy, three each in Spain and Portugal, two each in Canada and New Zealand and one in each of 11 other countries. Table 5 gives, for each study, the numbers of cases in each time period pre-and post-ban, and the estimated ban effect. Of the 41 estimates (study S51 providing two estimates), 30 were below 1, 11 significantly so (at p < 0.05), and eleven were above 1, six significantly. The random-effects meta-analysis estimate is 0.98 (95% CI 0.96-1.00).
Alternative estimates
As shown in Table 6 , alternatives to our main estimates described above in Table 3, Tables 4 and 5 could be derived for 34 of the 59 studies. Three of the alternative estimates were where our RRs had been derived using control data, but where it was also possible to ignore the control data and adjust for trend. The alternative estimate is somewhat higher in two studies and lower in one.
There were 31 cases where one could derive estimates based on rates as alternatives to the rates based on numbers presented in Table 3 . The pairs of RRs are always very similar, never differing by more than ± 0.02, and the random-effects estimates based on them, 0.99 (95% CI 0.96-1.01) using numbers and 0.99 (0.97-1.01) using rates, are also nearly identical.
For 25 studies considered in Table 5 where the estimate was based on linear trend, and there were at least three time periods pre-ban, it was possible to derive estimates allowing for a quadratic trend. Although there were more marked differences than for the comparison of RRs using numbers and rates, there is no consistent pattern to the difference and the random-effects estimates based on the pairs of estimates, 0.98 (0.96-1.01) for linear trend and 1.00 (0.97-1.03) for quadratic trend, are similar.
Since the alternative estimates had little overall effect, further analyses are based on our main estimates. Table 7 presents results of fixed-effect and random-effects metaanalysis based on the 62 estimates included in Tables 3-5 , and also Lee et al. Regulatory Toxicology and Pharmacology 101 (2019) 172-186 (continued on next page) P.N. Lee et al. Regulatory Toxicology and Pharmacology 101 (2019) 172-186 results of meta-analyses excluding various estimates from the analysis. It can be seen that in all seven analyses fixed-effect and random-effects estimates both showed some ban effect, and there is highly significant (p < 0.001) heterogeneity. Based on all 62 estimates, the random-effects estimate is 0.950 (05% CI 0.932-0.968). After excluding estimates where adjustment for trend was not possible, the ban effect becomes 0.971 (0.952-0.990), but further exclusion of regional estimates where national estimates were available leaves the estimate virtually unchanged, at 0.971 (0.944-0.999). Table 8 shows how ban effect estimates vary by eight different factors. Ban effects vary (p = 0.002) by weight of the estimate, due mainly to smaller RRs being seen in estimates with the least weight (< 100). Six of these were from the studies using control data, summarized in Table 4 , and this contributed to the significant variation (p < 0.001) by type of estimate, ban effects being greatest for estimates based on control data, and least for those when adjustment was made for linear trend (see Table 5 ). Clear evidence of variation is seen in relation to the length of the pre-ban period (p < 0.001), with studies having a shorter pre-ban period showing a greater ban effect. There is also clear evidence of variation by the length of the post-ban period (p < 0.001) but this did not show any clear trend. There is no significant evidence of variation by region or by age of the population studied. Nor does the ban effect vary significantly by the change in restrictiveness following a ban, though one can see rather greater ban effects where the change was greater.
Further meta-analyses
Discussion
Based on data for 59 studies providing estimations for AMI admissions (or a nearly equivalent definition), our overall estimate (randomeffects) of the ban effect is 0.950 (95% CI 0.932-0.968), which becomes 0.971 (0.944-0.999) when we exclude regional estimates where national estimates were available, and also exclude estimates where we could not adjust for the underlying time trend in AMI admission rates. The latter estimate is equivalent to a reduction in risk of 2.9% (0.01-5.6%) and is quite similar to our earlier estimate of 2.6% (1.1-4.0%), derived using similar methodology.
Our overall estimate of the ban effect is, as previously, based on a consistent approach, which involved comparison of numbers of cases pre-and post-ban, where possible adjusting for an underlying linear time trend using control data if available, or, if not, estimating the trend from the pre-and post-ban data. This would have been little changed by substituting alternative ban effect estimates based, where possible, on rates rather than numbers of cases (which made very little difference), or derived with adjustment for quadratic rather than linear trend. While, as noted by Barr et al. (2012) , adjusting for linear trends may be undesirable if underlying trends actually are non-linear, the lack of a consistent difference in direction between ban effects based on linear or quadratic adjustment does not suggest that our main estimates would have been materially biased.
Many of the estimates derived by the authors of the source papers are open to question for various reasons, including not accounting for seasonal variation, ignoring control data, not adjusting for the underlying trend, and even incorrect estimation of results. While we have used a consistent approach, which involved rejecting some candidate studies where the data presented did not permit accounting for seasonal variation or avoidance of very serious bias, our estimates still suffer from some weaknesses. These include the lack of national data for some countries, the possibility of publication bias (where some studies finding no effect were never published), "regression to the mean" (if bans tend to be introduced in areas with an AMI rate that, due partly to chance, may be unusually high) and failure to take into account the extent to which bans have been complied with. Also, our assumption that the ban effect is simply to multiply subsequent risk by a constant factor, rather than affecting the slope of the trend, might be incorrect. Nevertheless, we feel for various reasons that there is likely to be a real effect of smoking bans. These include the increased risk of heart disease in smokers, which declines quite rapidly on quitting, the increased risk in nonsmokers exposed to passive smoking, and the evidence that smoking bans reduce smoking prevalence, consumption per smoker and cotinine levels in nonsmokers. Also, fitting in with this is the evidence we present here suggesting that the effect of a ban may be greater for bans involving a greater change in restrictiveness.
We have previously (Lee and Fry, 2011; Lee et al., 2014 ) discussed weaknesses in earlier reviews that reported reductions in risk following bans that are implausibly much larger than the reductions which we find. While we do not repeat the arguments here, it is worth commenting on two reviews that have appeared since our previous review.
One of these (Jones et al., 2014 ) is a systematic review and metaanalysis of cardiovascular events following smoke-free legislations which, based on 31 studies providing estimates for 47 locations, reported "a 12% reduction in hospitalizations for acute coronary events (pooled RR: 0.88, 95% CI: 0.85-0.90)". Looking at the detail of the analysis, eight of the studies (Dove et al., 2010; Johnson and Beal, 2013; Lippert and Gustat, 2012; Naiman et al., 2010; Rodu et al., 2012; Sargent et al., 2012; Stallings-Smith et al., 2013; Vander Weg et al., 2012) were rejected in our previous review for reasons discussed there, including mortality data and lack of seasonal adjustment. The remaining studies are included in our analyses. The most notable thing about the review is that no account whatsoever is taken of any underlying trend in heart disease rates, and results for control populations are totally ignored. Indeed the only studies for which their ban effect estimates agree with ours are where the authors of the source paper carried out trend adjustment. The other review (Frazer et al., 2016) was from the Cochrane Collaboration and considered a wider range of endpoints. For cardiovascular health, they considered 44 studies, 43 of AMI and ACS and six of stroke. They assessed the evidence as being of "moderate" quality, but did not attempt meta-analyses. In their summary, they noted that "the best quality studies collected data at multiple time points before and after the introduction of a ban in order to adjust for existing time trends" and pointed out that "some studies could compare events rates in areas with and without bans, or where bans were introduced at different times". Of the 43 studies of AMI and ACS, five are not included in this review, four (Lippert and Gustat, 2012; Naiman et al., 2010; Sargent et al., 2012; Vander Weg et al., 2012) for reasons discussed earlier and one (Rajkumar et al., 2014) where the endpoint was inappropriate. The remaining studies are included in our analyses. The review only cites the results reported by the authors and does not attempt, as we do, to use the data reported to derive estimates.
Of the new studies incorporated in this update (S42-S59), the estimates presented in Tables 3 and 5 all fall in the range 0.83-1.17, with one exception, study S42, which reported a highly significant and massively reduced RR of 0.58 (95% CI 0.54-0.62). It is interesting to note that this study, conducted in Liverpool, reported that AMI admissions dropped from 1881 in 2005-2006 pre-ban to 1089 in 2011-2012 post-ban, but that, over the same period, coronary heart disease admissions increased from 13,434 to 15,523. It is interesting that the source paper (Liu et al., 2013) gives little attention to this gross difference, which to us suggests a change over time in the way diseases were classified, and even states that their estimated 42% reduction in AMI risk is "consistent with results in other settings and populations", when studies typically report much smaller ban effects.
Conclusions
This further update of the evidence relating smoking bans to incidence of heart disease confirms our previously reported conclusions (Lee and Fry, 2011; Lee et al., 2014 ) that ban effects are quite modest. Based on all 59 studies, the reduction is estimated to be by 5.0% (95% CI 3.2-6.8%), but excluding regional estimates where national estimates are available, and excluding studies where adjustment for the underlying trend was not possible reduces the estimate to 2.9% (0.01-5.6%). While some true ban effect seems likely, limitations of the data preclude a very confident conclusion.
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